SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications - PubMed
3 hours ago
- #SGLT2 inhibitors
- #cardio-metabolic-renal diseases
- #clinical evidence review
- SGLT2 inhibitors (SGLT2is), including dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin, are used to treat type 2 diabetes and have shown cardiovascular and renal benefits in large trials.
- Beyond lowering blood sugar, SGLT2is help reduce body weight and blood pressure, lower heart failure hospitalization risk, and slow chronic kidney disease progression, even in non-diabetic patients.
- These drugs are generally safe with manageable side effects like genital infections and dehydration, offering significant benefits over risks for most patients with cardio-metabolic-renal conditions.
- SGLT2is represent an important advance in treatment, potentially reducing long-term healthcare costs by delaying dialysis and hospital care, and supporting individualized therapeutic decision-making.